Quarterly ResultMay 14, 2026, 07:07 AM
Larimar to Initiate Rolling BLA for Nomlabofusp in June 2026
AI Summary
Larimar Therapeutics, Inc. announced its first quarter 2026 financial results and provided significant updates on its nomlabofusp program for Friedreich's ataxia. The company plans to initiate a rolling Biologics License Application (BLA) submission for accelerated approval in June 2026, with final modules expected in the second half of 2026. Larimar reported $200.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, extending its cash runway into Q2 2027. The US FDA also granted Breakthrough Therapy Designation to nomlabofusp in February 2026.
Key Highlights
- Larimar Therapeutics plans to initiate a rolling BLA submission for nomlabofusp in June 2026, seeking accelerated approval.
- The company reported $200.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
- Projected cash runway extends into the second quarter of 2027.
- Net loss for Q1 2026 was $29.6 million, or $0.31 per share, compared to $29.3 million in Q1 2025.
- Research and development expenses decreased to $25.0 million in Q1 2026 from $26.6 million in Q1 2025.
- General and administrative expenses increased to $6.1 million in Q1 2026 from $4.6 million in Q1 2025.
- Topline open-label study data to support BLA submission is expected in Q2 2026.
- The US FDA granted Breakthrough Therapy Designation to nomlabofusp in February.